Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06723119 · ClinicalTrials.gov registry record · NA
Effect of Resveratrol Supplementation on Exercise Performance and Recovery
A NA study of Effect of Resveratrol on Performance and Recovery, sponsored by University of Central Florida.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06723119: Recruiting NA study of Effect of Resveratrol on Performance and Recovery, sponsored by University of Central Florida.
NCT06723119 is a NA study of Effect of Resveratrol on Performance and Recovery that is actively recruiting participants, run by University of Central Florida. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06723119, a NA study of Effect of Resveratrol on Performance and Recovery, is actively recruiting participants, sponsored by University of Central Florida.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To examine the effects of once daily supplementation with 500mg VeriSperse® resveratrol (VRES) for 17 days on muscle function, delayed onset muscle soreness, systemic concentrations of muscular damage markers and markers of oxidative stress in resistance trained young adult males following a damaging isoinertial squat protocol (ISP).
Primary Outcome
Blood samples will be obtained at V2, PRE-, IP, 24H, 48H, and 72H using a 21-gauge vacutainer or 23-gauge butterfly needle from a superficial forearm vein. Up to 2 unsuccessful attempts in one arm, and with permission, a third attempt in the opposite arm, will be made. Three failed attempts will terminate the draw. Issues with blood collection devices will not remove participants from the study. All draws will follow aseptic conditions, with skin disinfected before insertion and the puncture sit
Conditions Studied
Interventions
- OTHER Resveratrol (VRES) 500 mg oral once daily.
- OTHER Placebo 500 mg oral once daily.
Study Locations (1)
Florida
- University of Central Florida EPIC Lab - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2025-04-01 |
| Phase | NA |
What NCT06723119 shows while recruiting
NCT06723119 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Effect of Resveratrol on Performance and Recovery appearing as the primary indexed condition, and to 2 interventions - of which Resveratrol (VRES) 500 mg oral once daily. is the first listed.
NCT06723119 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06723119 about?
NCT06723119 is a clinical study titled "Effect of Resveratrol Supplementation on Exercise Performance and Recovery". To examine the effects of once daily supplementation with 500mg VeriSperse® resveratrol (VRES) for 17 days on muscle function, delayed onset muscle soreness, systemic concentrations of muscular damage markers and markers of oxidative stress in resistance trained young adult males following a damagin...
What is the current status of trial NCT06723119?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-10-01. Estimated completion is 2025-04-01.
What conditions does trial NCT06723119 study?
This clinical trial studies the following conditions: Effect of Resveratrol on Performance and Recovery.
What interventions are being tested in trial NCT06723119?
The interventions under investigation include: Resveratrol (VRES) 500 mg oral once daily. (OTHER), Placebo 500 mg oral once daily. (OTHER).
Who is sponsoring clinical trial NCT06723119?
This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06723119 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06723119's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI